These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17313615)

  • 1. Insulin resistance and HIV infection: a review.
    Aboud M; Elgalib A; Kulasegaram R; Peters B
    Int J Clin Pract; 2007 Mar; 61(3):463-72. PubMed ID: 17313615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin Resistance and the cardiometabolic syndrome in HIV infection.
    Bevilacqua M; Dominguez LJ; Barbagallo M
    J Cardiometab Syndr; 2009; 4(1):40-3. PubMed ID: 19245515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.
    Samaras K
    J Antimicrob Chemother; 2008 Feb; 61(2):238-45. PubMed ID: 18070830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
    Calza L; Manfredi R; Chiodo F
    J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection.
    Samaras K; Gan SK; Peake PW; Carr A; Campbell LV
    Obesity (Silver Spring); 2009 Jan; 17(1):53-9. PubMed ID: 19008869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand.
    Lee B; Aurpibul L; Sirisanthana V; Mangklabruks A; Sirisanthana T; Puthanakit T
    HIV Med; 2009 Feb; 10(2):72-8. PubMed ID: 19018877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
    Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
    Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk.
    Barbaro G
    Am J Ther; 2006; 13(3):248-60. PubMed ID: 16772767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HIV infection: emerging issues and new challenges].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2006 Dec; 97(12):771-80. PubMed ID: 17252736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular injury, hypertension and coronary artery disease in human immunodeficiency virus infection.
    Barbaro G
    Clin Ter; 2008; 159(1):51-5. PubMed ID: 18399263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2004 May; 95(5):265-75. PubMed ID: 15202680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
    Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
    AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance in treated HIV infection.
    Feeney ER; Mallon PW
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):443-58. PubMed ID: 21663838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Disorders of lipid and glucose metabolism. Long-term adverse effects of antiretroviral therapy].
    Landauer N; Goebel FD
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():16-8. PubMed ID: 12043065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease and toxicities related to HIV infection and its therapies.
    Zareba KM; Miller TL; Lipshultz SE
    Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diabetic ketoacidosis in an HIV-infected patient undergoing antiretroviral therapy].
    Holm MR; Hansen BR; Røder ME
    Ugeskr Laeger; 2006 Feb; 168(9):920-1. PubMed ID: 16513058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metabolic abnormalities, lipodystrophy and cardiovascular risk in HIV-infected patients].
    Leclercq P; Blanc M
    Rev Prat; 2006 May; 56(9):987-94. PubMed ID: 16775979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.